BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 16482210)

  • 21. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
    Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
    Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
    Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
    Jiang Q; Zhao XY; Qin YZ; Liu YR; Lai YY; Jiang B; Huang XJ
    Am J Hematol; 2012 Dec; 87(12):1065-9. PubMed ID: 22965919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.
    Piazza RG; Magistroni V; Franceschino A; Andreoni F; Tornaghi L; Colnaghi F; Corneo G; Pogliani EM; Gambacorti-Passerini C
    Blood Cells Mol Dis; 2006; 37(2):111-5. PubMed ID: 16908206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
    Oshikawa G; Kurosu T; Arai A; Murakami N; Miura O
    Cancer Genet Cytogenet; 2010 May; 199(1):56-61. PubMed ID: 20417871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
    Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
    Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
    J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
    Ohm L; Arvidsson I; Barbany G; Hast R; Stenke L
    Am J Hematol; 2012 Aug; 87(8):760-5. PubMed ID: 22641468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
    Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; Dazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM
    Haematologica; 2003 Mar; 88(3):260-7. PubMed ID: 12651263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
    Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ
    Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
    Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C
    Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
    [No Abstract]   [Full Text] [Related]  

  • 37. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
    Marin D; Kaeda J; Szydlo R; Saunders S; Fleming A; Howard J; Andreasson C; Bua M; Olavarria E; Rahemtulla A; Dazzi F; Kanfer E; Goldman JM; Apperley JF
    Leukemia; 2005 Apr; 19(4):507-12. PubMed ID: 15703781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic and molecular mechanisms of resistance to imatinib.
    Hochhaus A
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):69-79. PubMed ID: 12783379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
    Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
    Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
    O'Dwyer ME; Gatter KM; Loriaux M; Druker BJ; Olson SB; Magenis RE; Lawce H; Mauro MJ; Maziarz RT; Braziel RM
    Leukemia; 2003 Mar; 17(3):481-7. PubMed ID: 12646934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.